177Lu-dotatate use in chronic kidney disease patients: A single center experience

医学 肾功能 肾脏疾病 泌尿科 内科学 放射性核素治疗 肌酐 单中心 白细胞减少症 胃肠病学 化疗
作者
Sandhya Manohar,Panagiotis Kompotiatis,Þorvarður R. Hálfdánarson,Timothy J. Hobday,Matthew Thorpe,Geoffrey B. Johnson,A. Tuba Kendi,Nelson Leung
出处
期刊:Journal of onco-nephrology [SAGE]
卷期号:5 (3): 162-171 被引量:4
标识
DOI:10.1177/23993693211050410
摘要

Background: Peptide receptor radionuclide therapy with 177 Lu-dotatate is a novel therapy for metastatic neuroendocrine cancers. It undergoes reabsorption at the proximal tubule; after the breakdown of the peptide fragment, 177 Lu is retained and continues its decay process exposing the nephron to continuous low dose radiation. Pivotal NETTER-1 trial did not include patients with eGFR <50 and so its effects in CKD patients is not known. Methods: We performed a retrospective chart review of all consecutive adult patients that received 177 Lu-dotatate over 1 year at Mayo Clinic, Rochester. We analyzed renal and hematological laboratory data obtained prior to each of four treatment cycles and at 3- and 6-month post completion of all treatment. We defined CKD as eGFR <60 ml/min and AKI as creatinine increase of ⩾0.3 from baseline by AKIN criteria. Results: Overall 86 patients were included in the study with 39 (45%) with known CKD. About three patients had CKD, four with eGFR of 20–30 ml/min. About 4 (4.6%) patients had AKI and the predominant cause being hypotension. Among the CKD patients the average eGFR improved after the first cycle of PRRT therapy from baseline of 49 (13) to 53.5 (17) ml/min ( p = 0.01) with no significant decline of renal function noted at 3- and 6-months post treatment follow up. Rate of thrombocytopenia and leukopenia were significantly more in the CKD patients starting even after single treatment. No drug dose correlation was noted. Conclusion: Patients with CKD are at a higher risk of hematological toxicity especially with thrombocytopenia and require close monitoring and ongoing dose adjustment. Ongoing safety studies to assess the long-term impact of 177 Lu-dotatate on the kidney are needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
iuv发布了新的文献求助10
2秒前
1111关注了科研通微信公众号
4秒前
科研通AI2S应助郝瑞之采纳,获得10
4秒前
斯文败类应助知涯采纳,获得10
5秒前
一枚小豆完成签到,获得积分10
5秒前
和谐翠丝发布了新的文献求助10
5秒前
Liu_Ci发布了新的文献求助10
5秒前
Agoni完成签到,获得积分10
7秒前
桐桐应助轩轩采纳,获得10
8秒前
oky完成签到 ,获得积分10
9秒前
9秒前
9秒前
haimianxi完成签到,获得积分10
9秒前
lala完成签到,获得积分20
9秒前
神内打工人完成签到 ,获得积分10
12秒前
烟云墨雨完成签到 ,获得积分10
12秒前
13秒前
13秒前
对于完成签到,获得积分10
13秒前
lishi发布了新的文献求助10
13秒前
huan完成签到,获得积分10
15秒前
16秒前
顾矜应助BSDL采纳,获得10
16秒前
19秒前
19秒前
白开水完成签到,获得积分10
21秒前
迷人的映雁完成签到,获得积分10
21秒前
chengyuan发布了新的文献求助10
22秒前
ZhihaoZhu发布了新的文献求助10
23秒前
L-g-b完成签到 ,获得积分10
23秒前
23秒前
抽烟不完成签到 ,获得积分10
23秒前
泽鑫发布了新的文献求助10
24秒前
24秒前
lishi完成签到,获得积分10
24秒前
25秒前
Heheya发布了新的文献求助10
25秒前
天天快乐应助可靠的南霜采纳,获得10
27秒前
InfoNinja应助风趣的烤鸡采纳,获得30
27秒前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3139078
求助须知:如何正确求助?哪些是违规求助? 2789947
关于积分的说明 7793264
捐赠科研通 2446392
什么是DOI,文献DOI怎么找? 1301085
科研通“疑难数据库(出版商)”最低求助积分说明 626105
版权声明 601102